Antioxidative hypoglycemic herbal medicines with in vivo and in vitro activity against C-reactive protein; a

Maryam Mirahmad1, Shahrzad Mohseni1, Ozra Tabatabaei-Malazy2

  • 1Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Insights

This systematic review found that numerous herbal medicines effectively reduce C-reactive protein (CRP) and oxidative stress in animal models of type 2 diabetes mellitus (T2DM). These natural compounds show promise for managing diabetes complications.

Area of Science:

  • Pharmacology
  • Natural Product Research
  • Endocrinology

Background:

  • Inflammation plays a critical role in type 2 diabetes mellitus (T2DM) pathophysiology.
  • Current T2DM treatments have limitations, driving interest in natural products.
  • C-reactive protein (CRP) is a key inflammatory marker in T2DM management.

Approach:

  • Systematic review of literature up to August 2021.
  • Searched PubMed, Scopus, Web of Science, and Cochran Library for studies on herbal medicine, diabetes, CRP, and antioxidants.
  • Assessed evidence quality using SYRCLE's tool and registered protocol in PROSPERO.

Key Points:

  • Twenty-three experimental studies were included from 9904 initial articles.
  • Numerous herbal medicines demonstrated efficacy in reducing CRP and oxidative stress in T2DM animal models.
  • Specific plants like Psidium guajava, Punica granatum, and Curcuma longa showed significant effects, with some exhibiting neuroprotective properties.

Conclusions:

  • Hypoglycemic medicinal plants are promising regulators of CRP and oxidative stress in T2DM.
  • These plants offer potential for managing diabetes complications.
  • Further high-quality in vivo studies and clinical trials are needed to confirm efficacy.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
233
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
138